Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC in Peritoneal Carcinomatosis
NCT04329494Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Aug 2020
- Primary completion
- Jan 2028
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label trial of cisplatin, doxorubicin, oxaliplatin, mitomycin c and paclitaxel in peritoneal carcinomatosis (PC), ovarian cancer, uterine cancer and 3 more (4 arms), sponsored by City of Hope. Primary endpoints: Dose limiting toxicities at 18 weeks and Incidence of adverse events at 18 weeks. Started Aug 2020; status: recruiting.
02
Drugs
cisplatindoxorubicinoxaliplatinmitomycin cpaclitaxel
03
Conditions
peritoneal carcinomatosis (PC)ovarian canceruterine cancergastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04329494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329494.